Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia

Key Points

• This study aims to evaluate the safety and efficacy of base-edited CAR7 T cells in patients with relapsed T-cell acute lymphoblastic leukemia.
• Phase 1 clinical trial design
• Patients receiving base-edited CAR7 T cells
• Interim results assessed for safety and efficacy
• Interim results indicate promising safety profile of base-edited T cells in relapsed leukemia patients.
• Study suggests further investigation is warranted due to potential immunotherapy-related complications.